newsfilter
← Latest News
GlobeNewswire·

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

APMD
  • Apnimed's board compensation committee granted 14 new non-executive employees non-qualified stock options on November 2, 2026.
  • The total grant comprises 331,000 shares of common stock purchased under the 2026 Inducement Plan.
  • Each option carries an exercise price of $15.40 per share, matching the closing trading price on the grant date.
  • Vesting schedules begin one year after each employee's start date, with the first quarter vesting then monthly installments over the following three years.
  • Awards were issued as inducement material to new hires in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The 2026 Inducement Plan was adopted by the board on August 21, 2026.
  • Apnimed is a late-stage clinical company developing oral therapies for sleep-related breathing diseases, specifically advancing product candidate AD109 for OSA treatment.
  • Forward-looking statements regarding commercial readiness, AD109's potential, \& PDUFA timing are subject to risks detailed in SEC filings.